Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the potential role of dutasteride in prostate cancer prevention, examining its effects on risk, but does not report new clinical findings.

Human prostate cells produce more WISP1/CCN4 when there's not enough oxygen.

This study found that ureteroileal anastomosis with direct intraluminal visualization had a 4.2% stricture rate, which compares favorably to other techniques with rates between 3.5% and 11.1%.

This study demonstrated that methylation of the 5-alpha reductase type 2 (5-AR2) promoter is linked to reduced expression of the 5-AR2 protein, possibly explaining resistance to Finasteride in some BPH patients.

This article discusses historical aspects of gender development, particularly related to the discovery of finasteride, and reports no new clinical results.

This paper discusses socioeconomic factors affecting urological epidemiology and practice patterns but reports no new research findings.

This article discusses various studies in urology and reports no new research findings.

This article discusses the role of 5-alpha-reductase inhibitors in prostate cancer prevention and highlights a medical quandary, but it reports no new clinical findings.

This editorial comment in the Journal of Urology reviews various studies related to prostate cancer and therapies but reports no new research findings.

This letter to the editor discusses the relationship between lower urinary tract symptoms and erectile dysfunction as reported in a previous study, but presents no new findings.

This editorial comments on long-term treatment options for benign prostatic hyperplasia but reports no new research findings.

This editorial comment discusses combination therapy for benign prostatic hyperplasia but presents no new research findings.

Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.

Finasteride reduces bleeding risk during prostate surgery.

This editorial comment discusses the rationale and design of the REDUCE trial for prostate cancer chemoprevention and reports no new research findings.

This editorial comment references research on finasteride's effects on urinary retention and surgical needs in benign prostatic hyperplasia but reports no new findings.

This study investigates the potential influence of genetic variations in the 5α-reductase type 2 gene on the effectiveness of finasteride treatment for benign prostatic hyperplasia, but it reports no new clinical results.

This paper discusses the effect of dutasteride on prostate cancer detection in men with benign prostatic hyperplasia but provides no new clinical results.

This erratum addresses the long-term effects of finasteride on prostate-specific antigen levels but reports no new research findings.

Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.

This study reviews three years of experience using Finasteride to treat recurrent priapism in sickle cell anemia and reports no new research findings.

This article discusses developments in clinical urology featured in the Journal of Urology's October 1999 issue and presents no new clinical findings.

This case-control study found that men with earlier onset androgenetic alopecia, particularly frontal balding, may have an increased risk of prostate cancer in a multiethnic veterans cohort.

This study observed that despite the increase in nocturia cases from 2016 to 2021, the use of pharmacotherapy for the condition declined, suggesting potential undertreatment.

This study suggests that adopting the Mark Cuban Cost Plus Drug Company model for purchasing urological medications could have saved Medicare about $1.29 billion in 2020.

This study found that sociodemographic factors influence the likelihood of recurrent urinary retention episodes and the decision to undergo bladder outlet procedures, with only 6.4% of patients receiving such procedures despite their potential cost benefits.

In this study, men with persistent sexual dysfunction after stopping finasteride showed significant vascular, neurologic, and hormonal abnormalities, with severe erectile dysfunction being common.

This study found a significant association between finasteride use and reports of sexual dysfunction, particularly greater in young men using it for alopecia compared to older BPH patients.

This review discusses FAERS data on 5-alpha reductase inhibitors and their potential implications for post-finasteride syndrome, but it does not report any new clinical results.

This study found that patients with BPH who received finasteride before TURP experienced reduced intraoperative blood loss and improved quality of life one month after surgery compared to those who did not.